CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 914 enrolled
Drug / intervention
SCH 39641 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01469182
NCT01469182Phase 3Completed
CompareCT.gov

A 28-Day Study Evaluating the Safety of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet (SCH 39641/MK-3641) Treatment in Ragweed Allergic Adults (Phase 3, Protocol No.P05751)

ALK-Abelló A/S·interventional·Posted Nov 10, 2011·Updated Mar 3, 2017

In Brief

A Phase 3 clinical trial evaluating SCH 39641 and Placebo for SCH 39641 for Allergy. Completed, enrolled 914 participants.

Detailed Summary

This study assessed the safety profile of short ragweed (Ambrosia artemisiifolia) in participants with ragweed-induced rhinoconjunctivitis with or without asthma. The primary objective was to compare treatment-emergent adverse events (AEs) for participants treated with short ragweed allergy immunotherapy tablet (AIT) with those treated with placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergy
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 10, 2011
Enrollment StartNov 1, 2011
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 14.6 years ago

Interventions

SCH 39641biological

Rapidly dissolving tablet sublingually once daily

Placebo for SCH 39641drug

Rapidly dissolving tablet sublingually once daily